1. Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;91:1596–1604.
2. Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395–408.
3. Oliva EN, Dimitrov BD, Benedetto F, D‘Angelo A, et al. Hemoglobin level threshold for cardiac remodelling and quality of life in myelodysplastic syndrome. Leukemia Research 2005;29:1217–9.
4. Moyo V, Lefebvre P, Duh MS, Yektashenas B, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527–36.
5. Mundle S, Lefebvre P, Vekeman F, Duh MS, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009;115:706–15.
6. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92:68–75.
7. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574–82.
8. Tehranchi R, Fadeel B, Schmidt-Mende J, et al. Anti-apoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res 2005;11:6291–9.
9. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037–46.
10. Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607–13.
11. Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients with low-risk myelodysplastic syndrome: Update including extended treatment [abstract]. Blood 2007;110:81a.
12. Fenaux P, Kantarjian H, Lyons R, et al. An open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes [abstract]. Blood 2009;114:1081a.
13. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28:437–44.
14. Greenberg P, Garcia-Manero G, Moore MR, et al. Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine [abstract]. Blood 2009;114:703a.
15. Lyons RM, Larson RA, Kosmo MA, et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide [abstract]. Blood 2009;114:703a.
16. Sloand EM, Olnes MJ, Weinstein B, Scheinberg P, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions [abstract]. Blood 2009;114:53a.
17. Strupp C, Germing U, Aivado M, Misgeld E, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002;16:1–6.
18. Strupp C, Hildebrandt B, Germing U, Haas R, et al. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 2003;27:397–404.
19. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–65.
20. Giagounidis AA, Haase S, Heinsch M, Göhring G, et al. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q) MDS patients with unexpected responses. Ann Hematol 2007;86:133–7.
21. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86–93.
22. Giagounidis A, Fenaux P, Mufti G, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008;87:345–52.
23. Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008;26:5943–49.
24. Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors, and rates of leukemic transformation in a multicenter study of 303 untreated patients with MDS and del(5q) [abstract]. Blood 2009;114:390a.
25. Göhring G, Giagounidis A, Büsche G, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2009 Oct 24: [Epub ahead of print].
26. Fenaux P, Mufti G, Hellström-Lindberg E, et al. Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology 2009;10:223–32.
27. Denzlinger C, Bowen D, Benz D, Gelly K, et al. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. Br J Haematol 2000;208:95–6.
28. Knipp S, Hildebrand B, Kündgen A, et al. Intensive chemotherapy is not recommended for patients aged > 60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007;110:345–52.
29. Gore SD. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. J Natl Compr Canc Netw 2006;4:83–90.
30. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315–25.
31. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–40.
32. Silverman L, Fenaux P, Mufti G, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients with myelodysplastic syndromes (MDS). Blood 2008;112:91a.
33. Cheson BD, Bennett JM, Kantarjian H, et al. World Health Organization (WHO) international working group. Report on an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–4.
34. List AF, Fenaux P, Mufti G, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission [abstract no. 7006]. J Clin Oncol. 2008;26(Suppl 15):373s.
35. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:1850–6.
36. Maurillo L, Spagnoli A, Genuardi M, et al. 5-azacytidine for the treatment of acute myeloid leukemia: a retrospective, multicenter study of 55 patients [abstract]. Blood 2008;112:679a.
37. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):21–9.
38. Garcia-Manero G, Gore SD, Skikne B, et al. A phase 1, open-label, dose-escalation study to evaluate the safety, pharmacokinetcs, and pharmacodynamics of oral azacitidine in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). Blood 2009;114:53a.
39. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2‘-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956–62.
40. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–1803.
41. Kantarjian HM, O´Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133–7.
42. Steensma D, Baer MR, Slack JL, et al. Multicenter study of decitabine administered for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842–8.
43. Wijermans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood 2008;112:90a.
44. Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacytidine prolongs overall survival in patients with myelodysplastic syndrome – systematic review and meta-analysis. Haematologica 2009:[Epub ahead of print].
45. Kumar A, List AF, Hozo I, Komrokji R, et al. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndromes: adjusted indirect meta-analysis. Haematologica 2009:[Epub ahead of print].
46. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009;23:1019–28.
47. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008;49:690–5.
48. Möller I, Blum S, Gattermann N, et al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Ann Hematol 2009;88:1141–4.
49. Khan R, Schmidt-Mende J, Karimi M, et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008;36:149–57.
50. Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005;84:61–6.
51. Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008;87:601–11.
52. Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: Newer agents and the role of combination approaches. Cancer Control 2008;15(Suppl):40–9.
53. Kuendgen A, Bug G, Ottmann OG, et al. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid [abstract]. Blood 2008;112:1245a.
54. Leitch HA, Leger CS, Goodman TA, et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leukemia 2008;2:205–11.
55. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy on survival in regularly transfused MDS patients. A prospective analysis by the GFM [abstract]. Blood 2007;110:80a.
56. Fox F, Kündgen A, Nachtkamp K, et al. Matched-pair analysis of 186 MDS patients receiving long-term iron chelation therapy or transfusion therapy only [abstract]. Blood 2009;114:694a
57. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009 Aug 26: [Epub ahead of print].
58. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood 2008;112:238a.
59. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24–9.
60. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol 2008;80:168–76.
61. List A, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes [abstract]. Blood 2008;112:236a.
62. Gattermann N, Schmid M, Della Porta M, et al. Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial [abstract]. Blood 2008;112:235a.
63. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1,744 patients with transfusion-dependent anemias. Haematologica 2009 Nov 30: [Epub ahead of print].
64. Swerdlow SH, Campo E, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoetic and lymphoid tissues. Lyon: IARC Press, 4. Auflage, 2008.
65. Greenberg P, Cox C, Le Beau MM, Fenaux P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88.
66. Pagliuca A, et al. Haemato-Oncology Task Force of the British Committee for Standards in Haematology: Guidelines on the use of colony-stimulating factors in haematological malignancies. Br J Haematol 2003;123:22–3.
67. Smith TJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205.
68. Heuser M, Ganser A. Colony-stimulating factors in the management of neutropenia and its complications. Ann Hematol 2005;84:697–708.
Prof. Dr. med. Norbert Gattermann, Universitätsklinikum Düsseldorf, Klinik für Hämatologie, Onkologie und klinische Immunologie, Moorenstraße 5, 40225 Düsseldorf, E-Mail: Gattermann@med.uni-duesseldorf.de